Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Purmer

Cardiovascular Disease Thousand Oaks, CA Medical Doctor

NPI 1124058169 CMS profile 95619

1000 Newbury Rd, Suite 180, Thousand Oaks, CA 91320

Open in the dashboard

General payments

$21,362

1,072 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Purmer of Thousand Oaks, CA is reported in the CMS Open Payments database as having received $21,362 across 1,072 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,901 134
2024 General $2,688 133
2023 General $2,829 127
2022 General $3,266 162
2021 General $3,826 202
2020 General $2,704 142
2019 General $3,148 172

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Purmer
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Christopher Purmer were reported at $2,901. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Christopher Purmer Cardiovascular Disease median Middle half National median
2019 $3,148 $450 $127–$1,392 $163
2020 $2,704 $242 $77–$751 $114
2021 $3,826 $335 $101–$1,037 $132
2022 $3,266 $395 $121–$1,211 $149
2023 $2,829 $443 $136–$1,283 $160
2024 $2,688 $450 $136–$1,323 $164
2025 $2,901 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $2,029 109 payments
  2. Novartis Pharmaceuticals Corporation $1,704 112 payments
  3. AstraZeneca Pharmaceuticals LP $1,686 91 payments
  4. Biotronik Inc. $1,117 21 payments
  5. Abbott Laboratories $1,114 21 payments
  6. Merck Sharp & Dohme Corporation $1,019 40 payments
  7. Medtronic, Inc. $987 47 payments
  8. E.R. Squibb & Sons, L.L.C. $955 61 payments
  9. Amarin Pharma Inc. $902 43 payments
  10. Sanofi-Aventis U.S. LLC $890 42 payments
  11. Other $8,960 485 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $21,028 1,063 payments
  2. Education $334 9 payments
Products named General payments · program years 2019–2025
  1. Repatha $1,810 91 payments
  2. VERQUVO $1,270 49 payments
  3. ENTRESTO $905 72 payments
  4. BRILINTA $905 46 payments
  5. XARELTO $821 60 payments
  6. LEQVIO $710 36 payments
  7. Vascepa $644 29 payments
  8. FARXIGA $640 39 payments
  9. ELIQUIS $631 40 payments
  10. LifeVest $621 56 payments
  11. Other $15,096 667 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 87 drugs

Part D claims

8,546

Median for Cardiology: 2,533

Drug cost

$2,086,893

Median for Cardiology: $485,213

Branded share of claims

27.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 669 $850,811
Xarelto Rivaroxaban Brand 193 $261,062
Repatha Sureclick Evolocumab Brand 186 $215,357
Entresto Sacubitril/Valsartan Brand 104 $143,596
Farxiga Dapagliflozin Propanediol Brand 99 $101,019
Jardiance Empagliflozin Brand 59 $92,946
Repatha Pushtronex Evolocumab Brand 54 $49,539
Multaq Dronedarone Hcl Brand 37 $43,362
Repatha Syringe Evolocumab Brand 32 $35,372
Ozempic Semaglutide Brand 22 $22,820

The 10 drugs with the highest cost, of 87 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$594,368

Medicare's payments for the services billed

Medicare patients

2,108

Average age 79

Services billed

6,443

1,020 women, 1,088 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 49%
Atrial fibrillation 36%
Diabetes 29%
Chronic kidney disease 28%
Heart failure 26%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
$251 — —
Repatha
$224 272 —
VYNDAQEL
$175 — —
Arcalyst
$164 — —
FARXIGA
$134 99 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

1,072 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record